Celgene (NASDAQ:CELG) issued an update on its FY 2018 earnings guidance on Monday morning. The company provided earnings per share guidance of $8.75-8.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.79. The company issued revenue guidance of $15.2-15.2 billion, compared to the consensus revenue estimate of $15.23 billion.Celgene also updated its FY 2019 guidance to $10.60-10.80 EPS.
Shares of NASDAQ CELG opened at $84.90 on Monday. The company has a debt-to-equity ratio of 4.06, a current ratio of 2.13 and a quick ratio of 1.99. The stock has a market capitalization of $59.37 billion, a price-to-earnings ratio of 12.41, a price-to-earnings-growth ratio of 0.43 and a beta of 1.44. Celgene has a fifty-two week low of $58.59 and a fifty-two week high of $107.29.
Celgene (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $2.29 earnings per share for the quarter, topping the consensus estimate of $2.02 by $0.27. The business had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.83 billion. Celgene had a return on equity of 108.76% and a net margin of 19.64%. On average, equities analysts anticipate that Celgene will post 7.45 earnings per share for the current year.
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Read More: Liquidity
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.